Daratumumab
Daratumumab is a therapeutic monoclonal antibody used in combination regimens for plasma-cell disorders, particularly multiple myeloma and systemic light-chain (AL) amyloidosis.
Daratumumab is a therapeutic monoclonal antibody used in combination regimens for plasma-cell disorders, particularly multiple myeloma and systemic light-chain (AL) amyloidosis. Its clinical role is assessed through disease- and treatment-specific outcomes including overall response rate, complete response, hematologic complete response, minimal residual disease negativity, progression-free survival, survival, and organ responses such as cardiac response and renal function.
In multiple myeloma, daratumumab has been studied with dexamethasone, lenalidomide, bortezomib, cyclophosphamide, and other agents across newly diagnosed and relapsed disease settings. In AL amyloidosis, daratumumab-based therapy has been evaluated for clone-directed treatment, including regimens intended to improve the production of abnormal light chains and thereby reduce disease-related organ injury. The recent literature places daratumumab primarily within the themes of multiple myeloma treatment outcomes and AL amyloidosis response assessment, while also documenting treatment-related infection monitoring and its use in a case involving renal heavy-chain amyloidosis.
Where the papers sit
9 papers from the last 6 months study daratumumab directly · updated from PubMed 9 Nov 2026
Study type 5 clinical trials · 2 observational · 1 preclinical · 1 unclassified
Themes 3 themes
-
Frontline Multiple Myeloma Therapy
Daratumumab-containing quadruplets are moving frontline treatment beyond VRd alone in newly diagnosed multiple myeloma. Comparisons with VRd emphasize deeper responses, minimal residual disease and longer progression-free survival across transplant-eligible and transplant-ineligible patients. Extended consolidation is being explored for high-risk disease, while retrospective data continue to define safety with lenalidomide, bortezomib and dexamethasone. Economic analyses increasingly support the added cost of daratumumab when these clinical gains are sustained.
5 papers · 55.6%
-
CD38 Antibody Therapy
CD38 antibody work links membrane organization with combination treatment in relapsed multiple myeloma. Expansion microscopy localizes therapeutic antibody–receptor complexes to cholesterol-rich membrane domains, providing a mechanistic view of target engagement. The clinical study tests whether adding daratumumab to ixazomib, cyclophosphamide and dexamethasone improves treatment in relapse. The cluster is coherent around CD38-directed therapy but does not establish a single broader treatment trend.
2 papers · 22.2%
-
Cardiac AL Amyloidosis
Cardiac involvement is becoming the central challenge in AL amyloidosis diagnosis, treatment and prognosis. Real-world Chinese data define treatment patterns and outcomes across the disease, while a phase 2 study tests daratumumab monotherapy in newly diagnosed cardiac stage IIIb patients. Cardiac overall response and rapid control of the plasma-cell clone are key endpoints in this high-risk population. Whether hematologic responses consistently translate into cardiac recovery and longer survival remains unresolved.
2 papers · 22.2%
Papers
The 9 papers from the last 6 months that study daratumumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Frontline Multiple Myeloma Therapy (5)
- Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation. Journal of managed care & specialty pharmacy · 11 Sept 2026 PMID 42726291
- Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial. The Lancet. Oncology · 7 Sept 2026 PMID 42705255
- Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future oncology (London, England) · 14 Jul 2026 PMID 42444515
- Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. Blood advances · 3 Jun 2026 PMID 42234958
- The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database. Naunyn-Schmiedeberg's archives of pharmacology · 22 May 2026 PMID 42171749
CD38 Antibody Therapy (2)
- Expansion Microscopy Reveals the Spatial Association of Therapeutic Antibody-Receptor Complexes With Cholesterol-Rich Membrane Domains. Angewandte Chemie (International ed. in English) · 25 Aug 2026 PMID 42638193
- Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia · 18 Jun 2026 PMID 42315418
Cardiac AL Amyloidosis (2)
- A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis. American journal of hematology · 23 Jun 2026 PMID 42333973
- A phase 2 trial of daratumumab monotherapy for patients with newly diagnosed cardiac stage IIIb AL amyloidosis. Blood · 15 Jun 2026 PMID 42296025
By study type
Clinical trials (5)
- Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation. Journal of managed care & specialty pharmacy · 11 Sept 2026 PMID 42726291
- Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial. The Lancet. Oncology · 7 Sept 2026 PMID 42705255
- Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia · 18 Jun 2026 PMID 42315418
- A phase 2 trial of daratumumab monotherapy for patients with newly diagnosed cardiac stage IIIb AL amyloidosis. Blood · 15 Jun 2026 PMID 42296025
- Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. Blood advances · 3 Jun 2026 PMID 42234958
Observational studies and case reports (2)
- Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future oncology (London, England) · 14 Jul 2026 PMID 42444515
- A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis. American journal of hematology · 23 Jun 2026 PMID 42333973
Preclinical: animal, cell and lab studies (1)
- Expansion Microscopy Reveals the Spatial Association of Therapeutic Antibody-Receptor Complexes With Cholesterol-Rich Membrane Domains. Angewandte Chemie (International ed. in English) · 25 Aug 2026 PMID 42638193
Unclassified: not yet indexed with MeSH (1)
- The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database. Naunyn-Schmiedeberg's archives of pharmacology · 22 May 2026 PMID 42171749
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-09-02. Drafted by language models from published abstracts; not medical advice.